Glen Clack
Sheffield, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.
Journal: British journal of cancer
Published: January 16, 2026
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Journal: Nature communications
Published: March 06, 2025
A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants.
Journal: Advances in therapy
Published: July 22, 2024
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Journal: Nature communications
Published: August 07, 2023
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Journal: Nature communications
Published: September 27, 2022
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Journal: The oncologist
Published: September 12, 2022
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 06, 2021
Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
Journal: BMC cancer
Published: July 12, 2019
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Journal: Clinical and translational radiation oncology
Published: May 23, 2018
Clinical development of new drug-radiotherapy combinations.
Journal: Nature reviews. Clinical oncology
Published: June 02, 2016
Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 27, 2016
The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.
Journal: Toxicology and applied pharmacology
Published: November 12, 2015
Last Updated: 09/26/2026